The term sudden hypoacusis describes a hearing loss of rapid onset and unknown origin that can progress to severe deafness. Of the many therapeutic protocols that have been proposed for treating sudden hypoacusis, hyperbaric oxygen therapy (HOT) plays a leacling role. We studied50patients who had been referred to our ENTunit within 48 hours of the onset of sudden hypoacusis. We raiiclomly assigned30 of these patients to undergo oncedaily administration of HOT f o r I0 days; the other 20 patients were treated for I0 days with an intravenous vasodilator. Response to therapy in all patients was evaluated by calculating the mean hearing threshold at frequencies between 500 and 4,000 Hz and by assessing liininal tonal audiometry results recorded at baseline and I0 days after the cessation of treatment. These results, plus the findings of other audiologic and otoneurologic examinations, revealed that the patients in the HOTgroup experienced a significantly greater response to treatment than did those in the vasodilator group, regardless of age and sex variables. Significantly more patients in the HOT group experienced a good or significant response. I n both groups, patients with pantonal hypoacusis responcled significantly better than did those with a milder condition. Based on our findings, coupled with the fact that oxygen therapy is well tolerated andproduces no side effects, we conclude that HOT should be considered the preferred treatment f o r patients with sudden hypoacusis.
Introduction
Sudden hypoacusis is defined as a sensorineural hearing loss of rapid progression and unknown etiology that can progress to severe deafness. Tinnitus is often associated with this condition, but nonrecurrent vertigo is rare. Although the etiopathogenic mechanism of sudden hypoacusis is not known, the most common causes are believed to be either v i r a P or vascular in n a t~r e .~.~ Other proposed causes include autoimmune disorders8-l0 and a parcellar rupture of the labyrinthine membrane.' ' The difficulty in pinpointing the etiology of sudden hypoacusis has hindered efforts to treat it.'? Many treatment protocols have been proposed by various authors. Among the variety of drug therapies that have been used are vasodilators (e.g., carbogen, alpha blockers, and calcium antagonists) to improve oxygenation of the cochlear tissues,l3-l6 corticosteroids to counteract a possible autoimmune mechanism and to exert antiphlogistic and antiedematogenic effects,l0.I7 and osmotic drugs (e.g., mannitol) to modify the hydrostatic pressure of the perilymph and increase the amount of blood in the cochlea by creating an osmotic gradient between plasma and peri-
The use of dextran has also been suggested as a means of creating a hypervolemic hemodilution, thus causing a decrease in blood viscosity and an increase in cochlear blood f l o~.~~--'~ Some authors have employed normovolemic hemodilution to produce a decrease in hematocrit without reducing v~lemia.~~-** In addition to all these therapies, another effective treatment for sudden hypoacusis is hyperbaric oxygen therapy (HOT). 29 the amount of oxygen that is physically dissolved in plasma leads to an improvement of oxygen distribution throughout the tissues. The acoustic ciliate cells and the peripheral fibers of the acoustic nerve receive not only direct oxygenation via the bloodstream, but supplemental oxygenation through the perilymph and cortilyrnph." Moreover, oxygen therapy also facilitates cell metabolism, even when the blood supply is poor, and thus promotes a more rapid and complete functional recovery.
In this article, we describe our comparison of outcomes in a group of 50 patients with sudden hypoacusis who were treated with either HOT or intravenous vasodilation within 48 hours of the onset of their symptoms.
Pat ients and methods
We studied 50 patients with sudden hypoacusis of unknown etio logy who had been referred to the ENT Clinic at Pisa University within 48 hours of the onset of acute symptoms. Thirty of these patients (19 men and II women; mean age : 44 yr) were randomly assigned to undergo treatment with HOT , and 20 (II men and 9 women ; mean age: 47 yr) were selected for treatment with intravenous vasodilation. In the HOT group , pathologic anamnesis revealed that two patients had type 2 diabetes and one had mild arterial hypertension that was kept well under control with medication. In the vasodilator group , one patient had type 2 diabetes and two had arterial hypertension that was well controlled with drug therapy. We did not include in this study any patient who manifested a probable cause of sudden hypoacusis, such as acoustic trauma, a recent viral episode, or an important cardiovascular condition.
Pretreatment.
A diagnosis of sudden hypoacusis was confirmed in both groups by a series of baseline tests, including liminal tonal audiometry, tympanometry, and auditory evoked potentials (table) . Assessment of hearing loss in the tona l audiometric test was performed after classifying patients as having one of three categories of hypoacusis according to their pure-tone average (PTA) at 656 frequencies of 500, 1,000,2,000, and 4,000 Hz. The three categories were mild (PTA: :5:40 dB), moderate (PTA: >40 and :5:70 dB), and severe (PTA: >70 dB) .
At baseline, these tests revealed that 10 HOT patients (33.3%) had mild hypoacusis, II (36.7%) had moderate hypoacusis, and nine (30 %) had severe hypoacusis. The audiometric curve was flat in 13 patients (43.3%), upward-sloping in six (20%), and downward-sloping in 11 (36.7 %). Twenty-five of the 30 patients (83.3 %) complained of tinnitus in the affected ear.
In the vasodilator group, six patients (30 %) had mild hypoacusis, nine (45 %) had moderate hypoacusis, and five (25%) had severe hypoacusis. The liminal tonal audiometric test revealed a flat curve in 10 patients (50%), an upward -sloping curve in four (20 %), and a downwardsloping curve in six (30 %). Eighteen of these patients (90 %) repo rted tinnitus in the affec ted ear.
All patients also underwent four other pretreatment tests: videonystagmography to eval uate the vesti buloocular reflex , static posturography to test the vestibulospinal reflex , computed tomography (CT) and/or magnetic resonance imaging (MRI) of the head to look for pathology, and Doppler echo testing on the cerebroafferent vessels . Baseline videonystagmography revealed that four HOT patients (13.3 %) and five vasodilator patients (25%) had a peripheral vestibular deficit on the side of the hearing loss. Static posturography revealed that five patients in each group had postural instability with peripheral characteristics .
Treatment. The patients in the oxygen group underwent 10 once-daily sessions of HOT delivered in a multiperson chamber. Pure oxygen was administered through a mouth-and-nose mask at a constant level of2.2 atmospheric pressures (ATA) for 90 minutes per sessio n.
The patients in the medical therapy group underwent a 10-day course of intravenous vasodilator treatment (i.e ., single inject ions of 200 mg/day of buflomedil in 250 ml of physio logic solutio n). Our intention was to suspend Adverse reactions. judged byinvestigators to beat least possibly drug-related, occurringingrea terthanorequal to 1% ofmcxitlnxacin trea tedpatientswere : nausea (8%), diar rhea(6%). dizziness (3%), headache (2%). abdominalpain(2%), vomi ting (2%), taste perversion (1%), abnormal liver function test (1%), anddyspepsia (1%). Additional events, judged by investigators to be at least possibly drug-related, that occur redingreater than 0.05% and lessthan1% of mcxitlo xacin treatedpatientswere: 800Y ASA WHOLE: asthenia. moniliasis. pai n. malaise. lab testabnormal (not specified LABO RATOR YCHA NGES Changes in laboratory parameters, withou t regard to drug relationship, whicharenot listed above andwhich occurred in~2% 01 pat ientsand at anincidencegreater than incontrolsincluded: increases in MCH, neutrophils. wacs, PTratio. ionized calcium. chloride, albumin, globulin, bilirubin: decreases in hemoglobin, RBCs. neut rophils. ensinophils. basophils. PT ratio, glucose, p02, bilirubin and amylase . It cannot be determined if anyof theabove laboratory abno rmalities were caused by thedrugor theunderlying cond ilionbeing treated.
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Discussion
Eve n tho ugh the etiology of sud de n hypoacusis is unknow n, the therapeut ic approach to it is substantially the sa me as that take n for patient s for who m a ca use ofsudde n deafness ca n be traced.
hearing los s was mainly in the medi um to high freque ncie s (p<O.OS ). On the other hand, we found no stat istically sign ificant difference in improvement in either gro up between those who had pantonal sensorineural hypoacusis and those who had hypoacusis mainly at the low fre que ncies (upward-rising curve) . Likewise, there was no sig nifica nt difference in improvement in ei ther grou p betwe en those who had sensor ineu ral hypoacu sis in the med ium to high frequencies and those who had upward-slop ing curves . Analys is of auditory evoked potenti als con firmed the coc hlear patte rn and the beh avi or of heari ng recovery that was detected by liminal ton al audiometry.
Post-tre atment vide ony stagm ograph y showed that thre e HOT patient s ( 10%) and two vas od ilator patien ts (10 %) mai ntai ned persistent signs of a peripher al, compensatin g deficit. Static postu rogr aph y valu es show ed practicall y no change in either gro up .
Findings on CT and MRI were negati ve in all patient s, as were all neu rol ogic eva luatio ns an d all Dopp ler ec ho inve stigations of the cerebroafferent vesse ls (with the exception of five patients who ex hibi ted sligh t inti ma l thi ckenin g). treatmen t only if hearing recovered completely before the completion of the series (re lative gai n: 100%) , whic h occ urred in two patients.
1,000 Hz
Post-treatment . Baseline testing was repeated on all patients 10 days followi ng the cessation of therapy . Asses sments of bot h HOT and phar macologic therapy were based on a co mparison of baselin e and pos t-treat me nt PT A values. Responses were qua ntified by ca lculating the relative ga in (i.e., the value of the mean tot al gai n divid ed by the value of the mean initia l loss). Responses were cl assified as either go od (relative ga in:~SO % ) , significant (~2 S and <SO %) , or insign ificant «2S%).1. 28 St atistic al ca lculatio ns were ma de acco rding to an alysis of covariance, using baseline PT A values, age, and sex as co va ria nts . Wh en differences were statistica lly significant (p::;O.OS),a post hoc multiple co mpa rison (Bo nferro ni test) was perform ed.
Results
Li mina l tonal audiometric test results showed that the HOT group ex perie nced a significantly greater mean improvement in PTA values tha n did the vaso dilator group (relative ga in: 6 1.3 [±33 .6] vs 24 .0% [±22 .SJ; p = O.OOS ) (figu re I). Improvement wa s independent of age and sex.
Ana lysis of relative gains showed that 17 HOT patients (S6.7%) experienced a good recovery and eig ht (26 .7%) had a significant recovery, wh ile only five (16 .7%) had an insignificant response (figure 2). By co ntras t, only five vasodilator patient s (2S%) , ----------------------------------, had a goo d response and six (30 %) had a significant respon se; nine (4S%) had an insignificant respon se.
In both gro ups, patien ts w ith severe h yp oacu si s .cPT A: >70 dB ) experienced a sig nificantly greater impro vement (p<O.OS) than did those with mild hypoac usis (PTA: ::;40 dB). We did not find any sig nificant differences in eithe r gro up in the deg ree of improvemen t between those with mild and moderate hypoacusis or be tween those with moderate and se vere hypoacusis.
Patien ts in both gro ups who had apantonal type of hearing loss achieved a signifi cantl y higher relative ga in than did those whose audiometric curve and the degree of hypoacoustic symptom s. Moreover, in both groups of patients, the tre atment respon se was better in those who se hearing loss was pan tonal and in those who had severe hypoacusis (PTA : >70 dB).
Recovery in bo th gro ups was independent of age, sex , and the prese nce of any co nco mita nt d iseases. In addition, any association be tween hearing damage and ves tibular dam age (i.e. , unila teral canal paresis, which was presen t in 13.3% of the HOT pa tient s and 25 % of the vaso dilator patients) was no t considered to be predictive of a negati ve prog nosis .
Not only did HOT prod uce a greater relative auditory gain than did pharmacologic treatment , but a large majority of HOT patients ( On the basis of our findings and in light of the high degree of tolerability of this procedure, we believe that HOT must be con sidered the preferred treatment for sudden hypoacu sis. Viral and hydropic factors have been proposed by several authors as possible causes of sudden hypoacusis, wh ile oth er researchers be lieve that a vascular component play s an important role ."?It is we ll known that pro longed hypoxia can give rise to important perturbations in the auditory cells and eve n des troy them. In such cases, hearing dam age can be reversed if the vasc ular obst ruction is incomplete or if the labyrinth exe rts a pro tec tive mechanism aga inst the anoxic condition.
Sudden hyp oacusis de ma nds urgen t diagnosis and therapy in an oto lary ngo logy environment. Treatm ent should be starte d within 48 hours of the onset of symptoms to achieve the best chance of recovery. First introd uce d at the Marsei lle Sc hool in France, HOT has been used as a treatment for sudden hypoacusis for severa l decades.P-" HOT is based on the principle that a rise of at lea st 20 % ( 1.2 bar) in barometric pre ssure will cau se a partial rise in the blood oxygen level. High concentratio ns of pure oxygen in inspired air produce a considerable increase in the amount of oxygen that is physica lly dissolved in the blood-perhaps as muc h as 15 times more than what is dissolved at norma l atmospheric pressure (1.0 AT A). W hen air at 1.0 ATA is inhaled, on ly 0.32% of the volume of oxygen is phys ically dissol ved; when pure oxygen at 1.0 ATA is inha led , the volume ca n rise to as mu ch as 2.09 %, and at 2.0 ATA, it ca n increase to 4.44%.
HOT not only raises the amo unt of oxygen that is physica lly dissolved in the blood, it also increases the level of POl in the inner ear by means of diffusion thro ug h the round window and a subsequent increase in the proportion of oxygen that is disso lved in the labyrinthine liquids. Th e im proved oxygenation of the inner ea r act ivates cell metabolism and the Na +K+pu mp, and it leads to arestoration of the ionic balance and the electrophysiologic functions of the cochlea. HOT is also capab le of causing a reduction in hematocrit and blo od viscos ity, and thi s ca n have a rheo logic effect in the cochlear region." During HOT, therefore , hypoxic areas of the cochlea can be infused with high partial pre ssure s of oxygen , and thi s infusion gi ves rise to an acceleration of the biologic cellular mechanisms that are invol ved in functiona l recovery .
In our st udy , statistical analysi s showed that the HOT group had a sig nifica ntly greater recovery of hearing than did the vasodilator gro up (p=0.005). T he improveme nt in hearing threshold was associated with both the type of 
